Nuvation Bio (NUVB) Expected to Release Quarterly Earnings on Wednesday

Key Points

• Nuvation Bio is expected to report Q3 2026 results before the market opens on Wednesday, November 4. Analysts forecast a loss of $0.1236 per share and revenue of $34.39 million.
• In the prior quarter, Nuvation Bio reported a $0.15-per-share loss, missing estimates by $0.01, but revenue of $31.69 million exceeded expectations of $27.03 million.
• The stock opened at $4.54, well below its 52-week high of $9.75. Despite mixed analyst views, the shares carry a consensus “Moderate Buy” rating and a $13.22 target price.

Nuvation Bio (NYSE:NUVB - Get Free Report) is expected to be posting its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Nuvation Bio to post earnings of ($0.1236) per share and revenue of $34.39 million for the quarter. Parties are encouraged to explore the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

Nuvation Bio (NYSE:NUVB - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.01). The business had revenue of $31.69 million during the quarter, compared to the consensus estimate of $27.03 million. On average, analysts expect Nuvation Bio to post ($0.34) EPS for the current fiscal year and ($0.17) EPS for the next fiscal year.

Nuvation Bio Stock Performance

Shares of NYSE:NUVB opened at $4.54 on Wednesday. The stock has a market capitalization of $1.59 billion, a price-to-earnings ratio of -10.31 and a beta of 1.61. The stock's 50-day simple moving average is $5.77 and its two-hundred day simple moving average is $5.46. Nuvation Bio has a 52-week low of $3.92 and a 52-week high of $9.75.

Insiders Place Their Bets

In other Nuvation Bio news, insider Gary Hattersley sold 100,000 shares of the business's stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $7.09, for a total transaction of $709,000.00. Following the completion of the sale, the insider owned 100,000 shares of the company's stock, valued at approximately $709,000. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 30.11% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Nuvation Bio in a research note on Thursday, October 15th. Wall Street Zen lowered shares of Nuvation Bio from a "hold" rating to a "sell" rating in a research report on Saturday, October 10th. Citigroup restated a "market outperform" rating on shares of Nuvation Bio in a research report on Monday, October 19th. Wedbush reaffirmed an "outperform" rating and set a $11.00 target price on shares of Nuvation Bio in a report on Wednesday, September 16th. Finally, Citizens Jmp reiterated a "market outperform" rating and issued a $10.00 price target on shares of Nuvation Bio in a research report on Wednesday, September 16th. Nine equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $13.22.

Nuvation Bio Company Profile

Nuvation Bio, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with cancer. The company seeks to address areas of significant unmet need, with an emphasis on targeted therapies for solid tumors.

Nuvation Bio's lead product is taletrectinib, a next-generation tyrosine kinase inhibitor designed for patients with ROS1-positive non-small cell lung cancer (NSCLC), including certain tumors that have developed resistance to earlier ROS1-targeted treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.